Oxford Biomedica (LON:OXB) Reaches New 52-Week Low – Here’s What Happened

Oxford Biomedica plc (LON:OXB)’s share price hit a new 52-week low on Tuesday . The stock traded as low as GBX 431 and last traded at GBX 436.55, with a volume of 1907452 shares traded. The stock had previously closed at GBX 524.

Wall Street Analyst Weigh In

A number of research analysts have commented on OXB shares. Deutsche Bank Aktiengesellschaft cut shares of Oxford Biomedica to a “hold” rating and decreased their target price for the company from GBX 800 to GBX 595 in a research report on Tuesday, August 18th. Royal Bank Of Canada decreased their price objective on shares of Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating on the stock in a report on Monday, August 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 580.85.

Oxford Biomedica Stock Performance

The firm has a market capitalization of £541.04 million, a price-to-earnings ratio of -16.60 and a beta of 1.10. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16. The stock has a 50-day moving average price of GBX 569.98 and a 200 day moving average price of GBX 609.04.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.